The anti-GAPDH autoantibodies were associated with increased SLE disease activity and inflammation as well as increased intracranial pressure, which suggested that it could become a novel biomarker to evaluate the NPSLE activity. This evidence concerns the gene GAPDH and systemic lupus erythematosus.